Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Operating Leases (2020 - 2025)

Historic Operating Leases for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $29.7 million.

  • Relay Therapeutics' Operating Leases fell 3296.75% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.7 million, marking a year-over-year decrease of 3296.75%. This contributed to the annual value of $42.8 million for FY2024, which is 1180.78% down from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Operating Leases is $29.7 million, which was down 3296.75% from $30.7 million recorded in Q2 2025.
  • Relay Therapeutics' 5-year Operating Leases high stood at $54.6 million for Q3 2022, and its period low was $20.0 million during Q2 2022.
  • Over the past 5 years, Relay Therapeutics' median Operating Leases value was $42.8 million (recorded in 2024), while the average stood at $37.8 million.
  • As far as peak fluctuations go, Relay Therapeutics' Operating Leases soared by 15524.75% in 2023, and later tumbled by 3300.7% in 2025.
  • Quarter analysis of 5 years shows Relay Therapeutics' Operating Leases stood at $21.1 million in 2021, then skyrocketed by 153.92% to $53.5 million in 2022, then decreased by 9.28% to $48.5 million in 2023, then fell by 11.81% to $42.8 million in 2024, then plummeted by 30.6% to $29.7 million in 2025.
  • Its Operating Leases was $29.7 million in Q3 2025, compared to $30.7 million in Q2 2025 and $41.2 million in Q1 2025.